Addition of anti-CD25 to thymoglobulin for induction therapy: Delayed return of peripheral blood CD25-positive population

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n=88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1mg/kg) (n=27) or thymoglobulin alone (4-7 doses; 1mg/kg) (n=23). SPK recipients received daclizumab (two doses; 1mg/kg) in addition to thymoglobulin (five doses; 1mg/kg). The return of peripheral blood CD25+ cells was delayed for 45d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.

Original languageEnglish
JournalClinical Transplantation
Volume25
Issue number2
DOIs
StatePublished - Mar 1 2011

Fingerprint

Kidney
Pancreas
Population
Therapeutics
T-Lymphocyte Subsets
Organ Transplantation
thymoglobulin
Blood Cells
Flow Cytometry
Transplantation
Monoclonal Antibodies
Tissue Donors
Transplant Recipients
daclizumab

Keywords

  • IL-2 receptor
  • Kidney-pancreas transplant
  • T-cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Transplantation

Cite this

@article{3513cd2a05454ae694a584286f49f38d,
title = "Addition of anti-CD25 to thymoglobulin for induction therapy: Delayed return of peripheral blood CD25-positive population",
abstract = "An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n=88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1mg/kg) (n=27) or thymoglobulin alone (4-7 doses; 1mg/kg) (n=23). SPK recipients received daclizumab (two doses; 1mg/kg) in addition to thymoglobulin (five doses; 1mg/kg). The return of peripheral blood CD25+ cells was delayed for 45d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.",
keywords = "IL-2 receptor, Kidney-pancreas transplant, T-cells, Type 1 diabetes",
author = "Junichiro Sageshima and Gaetano Ciancio and Jeffrey Gaynor and Chen, {Linda J} and Giselle Guerra and Warren Kupin and David Roth and Phillip Ruiz and Burke, {George W}",
year = "2011",
month = "3",
day = "1",
doi = "10.1111/j.1399-0012.2010.01360.x",
language = "English",
volume = "25",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Addition of anti-CD25 to thymoglobulin for induction therapy

T2 - Delayed return of peripheral blood CD25-positive population

AU - Sageshima, Junichiro

AU - Ciancio, Gaetano

AU - Gaynor, Jeffrey

AU - Chen, Linda J

AU - Guerra, Giselle

AU - Kupin, Warren

AU - Roth, David

AU - Ruiz, Phillip

AU - Burke, George W

PY - 2011/3/1

Y1 - 2011/3/1

N2 - An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n=88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1mg/kg) (n=27) or thymoglobulin alone (4-7 doses; 1mg/kg) (n=23). SPK recipients received daclizumab (two doses; 1mg/kg) in addition to thymoglobulin (five doses; 1mg/kg). The return of peripheral blood CD25+ cells was delayed for 45d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.

AB - An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n=88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1mg/kg) (n=27) or thymoglobulin alone (4-7 doses; 1mg/kg) (n=23). SPK recipients received daclizumab (two doses; 1mg/kg) in addition to thymoglobulin (five doses; 1mg/kg). The return of peripheral blood CD25+ cells was delayed for 45d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.

KW - IL-2 receptor

KW - Kidney-pancreas transplant

KW - T-cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79953321610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953321610&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2010.01360.x

DO - 10.1111/j.1399-0012.2010.01360.x

M3 - Article

C2 - 21083765

AN - SCOPUS:79953321610

VL - 25

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 2

ER -